Tyson & Blake
Seed
Investment thesis
Tyson & Blake targets high-impact companies with strong growth potential that combine innovative technologies with distinctive business approaches. The firm prioritizes measurable outcomes and harnesses transformative technologies such as artificial intelligence to drive value creation. Its strategy emphasizes fostering innovation, purpose, and sustainable success while operating globally while maintaining strong local relationships and market insights.
Source: firm website, verified Jul 21, 2026.
Investments · 2 tracked
founders shown can be your intro pathFrequently asked questions
- What stage does Tyson & Blake invest at?
- Tyson & Blake invests at the Seed stage.
- What sectors does Tyson & Blake focus on?
- Tyson & Blake focuses on AI & Machine Learning, Digital Health, Fintech.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
Tennr streamlines patient flow in healthcare by automating referral management, insurance verification, clinical context aggregation, and appointment scheduling. The platform processes referrals and intake documentation for approximately 10% of Americans annually.
An AI-first venture capital firm founded in 2016 that invests across the full AI stack, including next-generation compute chips, AI infrastructure, robotics, and agentic AI solutions. The team originated from Stanford and leverages deep domain expertise and access to frontier research talent.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.